Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) are standard-of-care as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC) without actionable oncogenic driver mutations. While clinical trials demonstrated benefits of ICIs over chemotherapy, variation in outcomes across patients has been ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Brendel, Matthew, Wu, Ning, Ge, Wenzhen, Zhang, Hao, Rietschel, Petra, Quek, Ruben G. W., Pouliot, Jean-Francois, Wang, Fei, Harnett, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586943/
https://www.ncbi.nlm.nih.gov/pubmed/36271096
http://dx.doi.org/10.1038/s41598-022-20061-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586943/
https://www.ncbi.nlm.nih.gov/pubmed/36271096
http://dx.doi.org/10.1038/s41598-022-20061-6

Ejemplares similares